Given its significant association with key clinical biomarkers and poor prognosis, targeting FGF17 may represent a promising strategy for developing novel therapeutic interventions in NSCLC, potentially in combination with existing modalities such as immune checkpoint. This evidence concerns the gene FGF17 and non-small cell lung carcinoma.